|
Market Cap (4-Jul) $86,511,600 (718th) |
Close (30-Jun) $0.63 |
Volume (30-Jun) 55,179 |
Shortsold (19-Jun) 190,561 (0.07%) (455th) |
|
52w High $0.57 |
52w Low $0.275 |
P/E - |
EPS -0.09 |
RCE released this announcement to the ASX on 27 February 2023, 18:04. The announcement is marked as price sensitive, and is 23 page(s) in length and 312kb in size.
You can view all announcements from RCE and see how they appear on a price chart on the announcements page.
At the date of this announcement, RCE was 0.001% short sold according to ASIC data. It was ranked the 621st most shorted stock on the ASX. It is now ranked as the 455th most shorted stock on the ASX with 0.066% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from RCE | |
|---|---|
| Ethics Approval for Phase I/II UTI Trial Expansion | 29 June 2023, 13:49 |
| Change of Director's Interest Notice - J Graham | 26 June 2023, 15:58 |
| DFI Clinical Trial Outpatient Nurses Appointed | 29 May 2023, 10:54 |
| Appendix 4D and Interim Financial Report | 27 February 2023, 18:04 |
| Investor Presentation - Spark Plus Biotech Day | 24 February 2023, 10:56 |
| Recce Selects CMAX for Phase I/II UTI Clinical Trial | 20 February 2023, 9:41 |
| Cleansing Statement | 14 February 2023, 14:11 |
You must be logged in to post a reply.
Recce Pharmaceuticals Ltd 